摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氨基-6-羟基吡唑-(3,4-d)嘧啶 | 5472-41-3

中文名称
4-氨基-6-羟基吡唑-(3,4-d)嘧啶
中文别名
4-氨基-6-羟基吡唑并[3,4-d]嘧啶;4-氨基-6-羟基吡唑[3,4-d]嘧啶
英文名称
4-amino-1,7-dihydro-pyrazolo[3,4-d]pyrimidin-6-one
英文别名
4-Amino-1,7-dihydro-pyrazolo[3,4-d]pyrimidin-6-on;4-aminopyrazolo[3,4-d]pyrimidin-6-ol;4-amino-6-hydroxypyrazolo[3,4-d]pyrimi-dine;4-Amino-6-hydroxypyrazolo[3,4-d]pyrimidine;4-amino-1,5-dihydropyrazolo[3,4-d]pyrimidin-6-one
4-氨基-6-羟基吡唑-(3,4-d)嘧啶化学式
CAS
5472-41-3
化学式
C5H5N5O
mdl
MFCD00005689
分子量
151.128
InChiKey
KTQYLKORCCNJTQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    320 °C
  • 沸点:
    273.11°C (rough estimate)
  • 密度:
    1.4456 (rough estimate)
  • 最大波长(λmax):
    250nm(H2O)(lit.)
  • 稳定性/保质期:
    在常温常压下保持稳定

计算性质

  • 辛醇/水分配系数(LogP):
    -1.7
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    91.9
  • 氢给体数:
    3
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    T
  • 安全说明:
    S24/25
  • 危险类别码:
    R25
  • 海关编码:
    2933990090
  • WGK Germany:
    3
  • 储存条件:
    常温、避光、存放在阴凉干燥处并密封保存。

SDS

SDS:5d29a916b1f536b24a73c456817eba2e
查看
Name: 4-Amino-6-Hydroxypyrazolo[3 4-d]Pyrimidine 96% Material Safety Data Sheet
Synonym: 4-Aminopyrazolo(3,4-d)pyrimidine-6-ol
CAS: 5472-41-3
Section 1 - Chemical Product MSDS Name:4-Amino-6-Hydroxypyrazolo[3 4-d]Pyrimidine 96% Material Safety Data Sheet
Synonym:4-Aminopyrazolo(3,4-d)pyrimidine-6-ol

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
5472-41-3 4-Amino-6-Hydroxypyrazolo[3,4-d]Pyrimi 96 226-811-1
Hazard Symbols: None Listed.
Risk Phrases: None Listed.

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5472-41-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: beige
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: > 320 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H5N5O
Molecular Weight: 151.0679

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5472-41-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Amino-6-Hydroxypyrazolo[3,4-d]Pyrimidine - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 5472-41-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5472-41-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5472-41-3 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-氨基-6-羟基吡唑-(3,4-d)嘧啶N,O-双三甲硅基乙酰胺三氟甲磺酸三甲基硅酯 作用下, 以 甲醇乙腈 为溶剂, 反应 16.08h, 生成 4-amino-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine-6-one
    参考文献:
    名称:
    High-Throughput Five Minute Microwave Accelerated Glycosylation Approach to the Synthesis of Nucleoside Libraries
    摘要:
    [GRAPHICS]The Vorbruggen glycosylation reaction was adapted into a one-step 5 min/130 degrees C microwave assisted reaction. Triethanolamine in acetontrile containing 2% water was determined to be optimal for the neutralization of trimethylsilyl triflate allowing for direct MPLC purification of the reaction mixture. When coupled with a NH3/methanol deprotection reaction, a high-throughput method of nucleoside library synthesis was enabled. The method was demonstrated by examining the ribosylation of 48 nitrogen containing heteroaromatic bases that included 25 purines, four pyrazolopyrimidines, two 8-azapurines, one 2-azapurine, two imidazopyridines, two benzimidazoles, three imidazoles, three 1,2,4-triazoles, two pyrimidines, two 3-deazapyrimidines, one quinazolinedione, and one alloxazine. Of these, 32 yielded single regioisomer products, and six resulted in separable mixtures. Seven examples provided inseparable regioisomer mixtures of -two to three compounds (16 nucleosides), and three examples failed to yield isolable products. For the 45 single isomers isolated, the average two-step overall yield +/- SD was 26 +/- 16%, and the average purity +/- SD was 95 +/- 6%. A total of 58 different nucleosides were prepared of which 15 had not previously been accessed directly from glycosylation/deprotection of a readily available base.
    DOI:
    10.1021/jo061885l
  • 作为产物:
    参考文献:
    名称:
    Studies on Condensed Pyrimidine Systems. XV. Some Pyrazolo[3,4-d]pyrimidines
    摘要:
    DOI:
    10.1021/ja01594a046
点击查看最新优质反应信息

文献信息

  • Robins, Journal of the American Chemical Society, 1957, vol. 79, p. 6407,6412
    作者:Robins
    DOI:——
    日期:——
  • Potential Purine Antagonists. I. Synthesis of Some 4,6-Substituted Pyrazolo [3,4-d] pyrimidines<sup>1</sup>
    作者:Roland K. Robins
    DOI:10.1021/ja01585a023
    日期:1956.2
  • Communications - 4-Hydroxy-6-aminopyrazolo- [3,4-d] pyrimidine, a Potential Guanine Antagonist
    作者:R. Robins
    DOI:10.1021/jo01110a615
    日期:1956.4
  • High-Throughput Five Minute Microwave Accelerated Glycosylation Approach to the Synthesis of Nucleoside Libraries
    作者:Brett C. Bookser、Nicholas B. Raffaele
    DOI:10.1021/jo061885l
    日期:2007.1.1
    [GRAPHICS]The Vorbruggen glycosylation reaction was adapted into a one-step 5 min/130 degrees C microwave assisted reaction. Triethanolamine in acetontrile containing 2% water was determined to be optimal for the neutralization of trimethylsilyl triflate allowing for direct MPLC purification of the reaction mixture. When coupled with a NH3/methanol deprotection reaction, a high-throughput method of nucleoside library synthesis was enabled. The method was demonstrated by examining the ribosylation of 48 nitrogen containing heteroaromatic bases that included 25 purines, four pyrazolopyrimidines, two 8-azapurines, one 2-azapurine, two imidazopyridines, two benzimidazoles, three imidazoles, three 1,2,4-triazoles, two pyrimidines, two 3-deazapyrimidines, one quinazolinedione, and one alloxazine. Of these, 32 yielded single regioisomer products, and six resulted in separable mixtures. Seven examples provided inseparable regioisomer mixtures of -two to three compounds (16 nucleosides), and three examples failed to yield isolable products. For the 45 single isomers isolated, the average two-step overall yield +/- SD was 26 +/- 16%, and the average purity +/- SD was 95 +/- 6%. A total of 58 different nucleosides were prepared of which 15 had not previously been accessed directly from glycosylation/deprotection of a readily available base.
  • Studies on Condensed Pyrimidine Systems. XV. Some Pyrazolo[3,4-d]pyrimidines
    作者:Elvira A. Falco、George H. Hitchings
    DOI:10.1021/ja01594a046
    日期:1956.7
查看更多

同类化合物

阿拉格列汀 间型霉素环-3',5'-单磷酸酯 西地那非杂质 苯,[(1-甲基环戊基)硫代]- 苄基-(6-氯-1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 甲基-(6-甲基磺酰基-1(2)H-吡唑并[3,4-d]嘧啶-4-基)-胺 环己基-(1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 氮杂环庚-1-基-[7-氯-4-噻吩-2-基-2-(三氟甲基)-1,5,9-三氮杂双环[4.3.0]壬-2,4,6,8-四烯-8-基]甲酮 异丙基 4-(1-甲基-7-氧代-3-丙基-6,7-二氢-1H-吡唑并[4,3-d]嘧啶-5-基)噻吩-2-基磺酰基氨基甲酸酯 吡啶-2-基-[7-吡啶-4-基-吡唑[1,5-a]嘧啶-3-基]甲酮 吡唑并[2,3-a]嘧啶 吡唑并[1,5-a]嘧啶-7-胺 吡唑并[1,5-a]嘧啶-7(1h)-酮 吡唑并[1,5-a]嘧啶-6-醇 吡唑并[1,5-a]嘧啶-6-羧酸乙酯 吡唑并[1,5-a]嘧啶-6-羧酸 吡唑并[1,5-a]嘧啶-5-羧酸 吡唑并[1,5-a]嘧啶-3-胺盐酸盐(1:1) 吡唑并[1,5-a]嘧啶-3-胺;三氟乙酸 吡唑并[1,5-a]嘧啶-3-羰酰氯 吡唑并[1,5-a]嘧啶-3-羧酸乙酯 吡唑并[1,5-a]嘧啶-3-羧酸 吡唑并[1,5-a]嘧啶-3-磺酰胺 吡唑并[1,5-a]嘧啶-3-甲酰胺 吡唑并[1,5-a]嘧啶-3-甲腈 吡唑并[1,5-a]嘧啶-2-羧酸乙酯 吡唑并[1,5-a]嘧啶-2-羧酸 吡唑并[1,5-a]嘧啶,2-甲基-6-(1-甲基乙基)- 吡唑并[1,5-a]嘧啶,2-溴-5,7-二甲基- 吡唑并[1,5-A]嘧啶-5-胺 吡唑并[1,5-A]嘧啶-5(4H)-酮 吡唑并[1,5-A]嘧啶-3-甲醛 吡唑[1,5-A]嘧啶-5-羧酸甲酯 吡唑[1,5-A]嘧啶-5,7(4H,6H)-二酮 双氯地那非 别嘌醇 别嘌呤醇D2 二硫代乙基碳萘甲醚 二硫代-脱甲基-昔多芬 乙基7-甲基吡唑并[1,5-a]嘧啶-6-羧酸酯 [1,2]恶唑并[4,3-e]吡唑并[1,5-A]嘧啶 [(2S,5R)-5-(4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)四氢呋喃-2-基]甲醇 VEGFR2激酶抑制剂IV N5-(6-氨基己基)-N7-苄基-3-异丙基吡唑并[1,5-a]嘧啶-5,7-二胺 N5-(1-环庚基-1H-吡唑并[3,4-d]嘧啶-6-基)吡啶-2,5-二胺 N3-(4-氟苯基)-1H-吡唑并[3,4-D]嘧啶-3,4-二胺 N-苄基-6-氯-1H-吡唑并[3,4-d]嘧啶-4-胺 N-苄基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-甲基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-[2-(3-氨基-3-氧代丙氧基)乙基]-6-(4-溴苄基)吡唑并[1,5-a]嘧啶-3-甲酰胺